Lithuania IVD Market by Technology Molecular Diagnostics (Hepatitis C, Hepatitis B, Human Immunodeficiency Virus (HIV), Cytomegalovirus (CMV), Epstein–Barr virus (EBV), Tuberculosis, Sexually Transmitted Diseases (STDs), Hospital Acquired Infections, Respiratory Infections, Human Papillomavirus (HPV), Covid- 19), Tissue Diagnostics (H&E Stains, Special Stains, Advanced Stains, Digital Scanners), Sequencing (Clinical, NIPT and Research Use Only) Geography (Lithuania,), and forecast to 2029

Lithuania IVD market size was valued at Euro 42.5 million in 2022 and is poised to grow at a significant CAGR of 3.6% over 2023–2029. The Lithuania in-vitro diagnostics (IVD) market is a dynamic and rapidly evolving sector within the healthcare industry. IVD refers to medical devices and diagnostic techniques that are used to analyze samples derived from the human body, such as blood, urine, and tissue, outside the body. These tests provide crucial information for the early detection, diagnosis, and management of diseases and conditions. Molecular diagnostics in IVD market are growing at fastest rate due to increasing prevalence of various diseases such as Hepatitis B and C, Human Immunodeficiency Virus (HIV), Cytomegalovirus (CMV), Epstein–Barr virus (EBV), Tuberculosis, Sexually Transmitted Diseases (STDs), Hospital Acquired Infections, Respiratory Infections, Human Papillomavirus (HPV) and Covid- 19. In Lithuania, regular screening for blood donations is mostly done with NAT-based assays. Hepatitis C testing is also done on other demographic groups, such as medical staff, military people, and pregnant women, and is frequently done as part of clinical and scientific research. Every year, 1,500-2,000 persons in Lithuania infect with Hepatitis B, with around 100 of them developing jaundice. Within 6 months of developing acute viral hepatitis B, 90-98 percent of individuals recover fully and develop natural immunity. 5% of persons infected with HBV become chronic carriers, producing HBsAg and HBV-DNA on a long-term basis, and these infected donors are diagnosed by serology and NAT. HIV infections were reported in practically all administrative units of 60 municipalities in Lithuania. According to the ECDC report 2021, the number of newly diagnosed HIV cases gradually increased till 2017 and a downward trend was observed from 2017 to 2020. In 2017, the 263 new cases were recorded, and it reached to 108 cases by the end of 2020. Hospital-acquired infection is very high in Lithuania. Surgical site infections, catheter-associated urinary tract infections, ventilator-associated pneumonia, and healthcare-associated pneumonia, infections linked with endoscopic treatments, and Clostridium difficile infections are the most common hospital-acquired infections in Lithuania.